Bone Mineral Density Loss After Combat-Related Lower Extremity Amputation

被引:23
作者
Flint, James H. [1 ,2 ]
Wade, Alana M. [2 ]
Stocker, Derek J. [1 ]
Pasquina, Paul F. [1 ,2 ]
Howard, Robin S. [1 ]
Potter, Benjamin K. [1 ,2 ]
机构
[1] Walter Reed Natl Mil Med Ctr, Dept Orthopaed, Bethesda, MD 20889 USA
[2] Uniformed Serv Univ Hlth Sci, Dept Surg, Bethesda, MD 20814 USA
关键词
bone mineral density; amputation; lower extremity; combat; DEXA; MOLECULAR-WEIGHT HEPARINS; LOWER-LIMB AMPUTATION; INDUCED OSTEOPOROSIS; ORAL ALENDRONATE; ABOVE-KNEE; REHABILITATION; FRACTURES; RISK; OSTEOPENIA; AMPUTEES;
D O I
10.1097/BOT.0b013e3182a66a8a
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Objectives: Determine the incidence, severity, and associated risk factors for the development of low bone mineral density (BMD) after combat-related lower extremity amputation. Design: Retrospective case-control comparison. Setting: Tertiary care military treatment facility. Patients/Participants: One hundred fifty-six lower extremity amputees, representing 182 amputations (121 unilateral, 35 bilateral). Intervention: All patients underwent dual energy x-ray absorptiometry scanning during the treatment period. Main Outcome Measurements: The Z score was the main outcome measure. We identified all patients with low BMD (Z < -1.0) and conducted multivariate analysis to identify significant risk factors for low BMD development. Results: The observed rate of low BMD was 42%. The average Z score was -0.6 +/- 1.1 among unilateral amputations and -1.2 +/- 1.0 among bilateral amputations (P = 0.005). Risk factors for the development of low BMD were prolonged time to first ambulation [odds ratio (OR) = 1.39; 95% confidence interval (CI): 1.003-1.93; P = 0.048], prolonged time to dual energy x-ray absorptiometry (OR = 1.10; 95% CI: 1.02-1.18; P = 0.009), and more proximal amputation level (OR = 7.27; 95% CI: 3.21-16.49; P < 0.001). Among unilateral amputees, we detected a significant difference in the BMD of the intact and amputated limbs (-1.0; 95% CI: -1.1 to -0.8; P < 0.001). Conclusions: Proximal amputation level and delayed ambulation demonstrated a significant relationship with low BMD after traumatic and trauma-related amputation. We conclude that transfemoral amputees are at greater risk of BMD loss and that disuse atrophy is a primary factor in the development of low BMD. Prevention should focus on early and aggressive weight bearing rehabilitation and assessing levels and appropriately supplementing calcium and vitamin D. Level of Evidence: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.
引用
收藏
页码:238 / 244
页数:7
相关论文
共 42 条
  • [1] The correlation of bone mineral density and biochemical markers to fracture risk
    Adachi, JD
    [J]. CALCIFIED TISSUE INTERNATIONAL, 1996, 59 : S16 - S19
  • [2] [Anonymous], 1994, World Health Organ Tech Rep Ser, V843, P1
  • [3] Bernet V, 2009, J NUCL MED, V50
  • [4] Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis
    Bolland, Mark J.
    Grey, Andrew B.
    Gamble, Greg D.
    Reid, Ian R.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (03) : 1174 - 1181
  • [5] Ten years' experience with alendronate for osteoporosis in postmenopausal women
    Bone, HG
    Hosking, D
    Devogelaer, J
    Tucci, JR
    Emkey, RD
    Tonino, RP
    Rodriguez-Portales, JA
    Downs, RW
    Gupta, J
    Santora, AC
    Liberman, UA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (12) : 1189 - 1199
  • [6] BONE AND JOINT CHANGES IN LOWER-LIMB AMPUTEES
    BURKE, MJ
    ROMAN, V
    WRIGHT, V
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 1978, 37 (03) : 252 - 254
  • [7] Buzato MAD, 2002, ACTA CHIR BELG, V102, P248
  • [8] Changes in bone density after exposure to oral anticoagulants: A meta-analysis
    Caraballo, PJ
    Gabriel, SE
    Castro, MR
    Atkinson, EJ
    Melton, LJ
    [J]. OSTEOPOROSIS INTERNATIONAL, 1999, 9 (05) : 441 - 448
  • [9] Committee on Gynecologic Practice, 2008, OBSTET GYNECOL, V111, P1259
  • [10] Folwarczna J, 2005, PHARMACOL REP, V57, P635